Investor Announcement, Huntington's Disease,

Prana’s Huntington Disease trial analysis to feature at global movement disorder conference

Prana is pleased to announce that further analysis of the results of its REACH2HD trial will be featured at the 20th Annual International Movement Disorder Society Congress.


Movement disorders expert Professor Ira Shoulson joins Prana Biotechnology's Board of Directors

Email Newsletter

Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"